1. Record Nr. UNINA9910954395803321

| | |
|---|---|
| Autore | Patlak Margie |
| Titolo | Developing biomarker-based tools for cancer screening, diagnosis, and treatment : the state of the science, evaluation, implementation, and economics / / Margie Patlak and Sharyl Nass, rapporteurs ; National Cancer Policy Forum |
| Pubbl/distr/stampa | Washington, DC, : National Academies Press, c2006 |
| ISBN | 0-309-18061-9<br>1-280-70492-6<br>9786610704927<br>0-309-65814-4 |
| Edizione | [1st ed.] |
| Descrizione fisica | 1 online resource (112 p.) |
| Altri autori (Persone) | NassSharyl J |
| Disciplina | 616.99/4075 |
| Soggetti | Tumor markers<br>Biochemical markers |
| Lingua di pubblicazione | Inglese |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Note generali | Bibliographic Level Mode of Issuance: Monograph |
| Nota di bibliografia | Includes bibliographical references. |
| Nota di contenuto | Frontmatter -- Reviewers -- Contents -- Introduction -- Overview of Technologies Used to Discover Cancer Biomarkers -- Meeting the Technical Challenges of Biomarker Validation and Qualification -- Coordinating the Development of Biomarkers and Targeted Therapies -- Biomarker Development and Regulatory Oversight -- Assessment and Adoption of Biomarker-Based Technologies -- Economic Impact of Biomarkers -- Clinical Development Strategies for Biomarker Utilization Discussion -- Strategies for Implementing Standardized Biorepositories Discussion -- Strategies for Determining Analytic Validity and Clinical Utility of Biomarkers Discussion -- Strategies to Develop Biomarkers for Early Detection Discussion -- Mechanisms for Developing an Evidence Base Discussion -- Evaluation of Evidence in Decision Making Discussion -- Incorporating Biomarker Evidence Into Clinical Practice Discussion -- Acronyms -- Glossary -- References -- Appendixes -- Appendix A Workshop Agenda -- Appendix B Workshop Speakers, Moderators, Invited Discussants, and Participants. |
| Sommario/riassunto | Research has long sought to identify biomarkers that could detect |

cancer at an early stage, or predict the optimal cancer therapy for specific patients. Fueling interest in this research are recent technological advances in genomics, proteomics, and metabolomics that can enable researchers to capture the molecular fingerprints of specific cancers and fine-tune their classification according to the molecular defects they harbor. The discovery and development of new markers of cancer could potentially improve cancer screening, diagnosis, and treatment. Given the potential impact cancer biomarkers could have on the cost effectiveness of cancer detection and treatment, they could profoundly alter the economic burden of cancer as well. Despite the promise of cancer biomarkers, few biomarker-based cancer tests have entered the market, and the translation of research findings on cancer biomarkers into clinically useful tests seems to be lagging. This is perhaps not surprising given the technical, financial, regulatory, and social challenges linked to the discovery, development, validation, and incorporation of biomarker tests into clinical practice. To explore those challenges and ways to overcome them, the National Cancer Policy Forum held the conference "Developing Biomarker-Based Tools for Cancer Screening, Diagnosis and Treatment: The State of the Science, Evaluation, Implementation, and Economics" in Washington, D. C., from March 20 to 22, 2006. At this conference, experts gave presentations in one of six sessions. In addition, seven small group discussions explored the policy implications surrounding biomarker development and adoption into clinical practice. Developing Biomarker-based Tools for Developing Cancer Screening, Diagnosis, and Treatment: The State of the Science, Evaluation, Implementation, and Economics-Workshop Summary presents the conference proceedings and will be used by an Institute of Medicine (IOM) committee to develop consensus-based recommendations for moving the field of cancer biomarkers forward.